Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 571–580 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 571
- Medicine slug
- everolimus
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 20
- Source count
- 12
- Agreement rate
- 1
- Recorded readings
30 hours
- Numeric value
- 30
- Unit
- hours
- Source records
- 12
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 12 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e325efa-8ae6-4dac-b59b-d7c74c73186c (opens source in a new tab)
Everolimus label
Version not recorded · Effective date not recorded
Elimination The mean elimination half-life of everolimus is approximately 30 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f1ae129-c21e-4c25-84c1-a6757d9a7eb2 (opens source in a new tab)
Everolimus label
Version not recorded · Effective date not recorded
Elimination The mean elimination half-life of everolimus is approximately 30 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3bca36b-29ed-4a2b-a1be-a57b6af805f6 (opens source in a new tab)
Everolimus label
Version not recorded · Effective date not recorded
Elimination The mean elimination half-life of everolimus is approximately 30 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67e62e26-448d-46ec-b5a1-00dc1b5e26c6 (opens source in a new tab)
Everolimus label
Version not recorded · Effective date not recorded
Elimination The mean elimination half-life of everolimus is approximately 30 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5fb55800-f322-6bb6-9dde-622925ef28bd (opens source in a new tab)
Everolimus label
Version not recorded · Effective date not recorded
Elimination The mean elimination half-life of everolimus is approximately 30 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b809dfe-c076-07c5-207e-178c3f0d32d3 (opens source in a new tab)
Everolimus label
Version not recorded · Effective date not recorded
Elimination The mean elimination half-life of everolimus is approximately 30 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3dbbc24-7e55-4069-a305-e2cded2db641 (opens source in a new tab)
Everolimus label
Version not recorded · Effective date not recorded
Elimination The mean elimination half-life of everolimus is approximately 30 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01f7b5fb-be0d-4adf-acd2-6899018de966 (opens source in a new tab)
Everolimus label
Version not recorded · Effective date not recorded
Elimination The mean elimination half-life of everolimus is approximately 30 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c0075dd-a0a8-4dc4-be32-1be8383fbbdc (opens source in a new tab)
Everolimus label
Version not recorded · Effective date not recorded
Elimination The mean elimination half-life of everolimus is approximately 30 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2150f73a-179b-4afc-b8ce-67c85cc72f04 (opens source in a new tab)
Everolimus label
Version not recorded · Effective date not recorded
Elimination The mean elimination half-life of everolimus is approximately 30 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5cfca904-b75c-5a39-8cb9-b99bb421bceb (opens source in a new tab)
Everolimus label
Version not recorded · Effective date not recorded
Elimination The mean elimination half-life of everolimus is approximately 30 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5aaf2fb7-93f6-40d6-941a-9583a3794ce7 (opens source in a new tab)
Everolimus label
Version not recorded · Effective date not recorded
Elimination The mean elimination half-life of everolimus is approximately 30 hours.
Projected row 572
- Medicine slug
- everolimus
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 20
- Source count
- 20
- Agreement rate
- 1
- Recorded readings
74%
- Numeric value
- 74
- Unit
- %
- Source records
- 20
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 20 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e325efa-8ae6-4dac-b59b-d7c74c73186c (opens source in a new tab)
Everolimus label
Version not recorded · Effective date not recorded
Plasma protein binding is approximately 74% both in healthy subjects and in patients with moderate hepatic impairment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f1ae129-c21e-4c25-84c1-a6757d9a7eb2 (opens source in a new tab)
Everolimus label
Version not recorded · Effective date not recorded
Plasma protein binding is approximately 74% both in healthy subjects and in patients with moderate hepatic impairment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59cb86d5-8706-4619-b074-af253d3e0b68 (opens source in a new tab)
Everolimus label
Version not recorded · Effective date not recorded
Plasma protein binding is approximately 74% in healthy subjects and in patients with moderate hepatic impairment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d44998bb-5deb-4ee7-a0a5-979fe3f49557 (opens source in a new tab)
Everolimus label
Version not recorded · Effective date not recorded
Plasma protein binding is approximately 74% in healthy subjects and in patients with moderate hepatic impairment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cf2dd54b-7a1d-4401-9a01-75e68235e433 (opens source in a new tab)
Everolimus label
Version not recorded · Effective date not recorded
Plasma protein binding is approximately 74% in healthy subjects and in patients with moderate hepatic impairment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3bca36b-29ed-4a2b-a1be-a57b6af805f6 (opens source in a new tab)
Everolimus label
Version not recorded · Effective date not recorded
Plasma protein binding is approximately 74% both in healthy subjects and in patients with moderate hepatic impairment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43ef3c29-0e25-4fdd-aea1-06a20af9bbab (opens source in a new tab)
Everolimus label
Version not recorded · Effective date not recorded
Plasma protein binding is approximately 74% in healthy subjects and in patients with moderate hepatic impairment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67e62e26-448d-46ec-b5a1-00dc1b5e26c6 (opens source in a new tab)
Everolimus label
Version not recorded · Effective date not recorded
Plasma protein binding is approximately 74% both in healthy subjects and in patients with moderate hepatic impairment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5fb55800-f322-6bb6-9dde-622925ef28bd (opens source in a new tab)
Everolimus label
Version not recorded · Effective date not recorded
Plasma protein binding is approximately 74% both in healthy subjects and in patients with moderate hepatic impairment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b809dfe-c076-07c5-207e-178c3f0d32d3 (opens source in a new tab)
Everolimus label
Version not recorded · Effective date not recorded
Plasma protein binding is approximately 74% both in healthy subjects and in patients with moderate hepatic impairment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3dbbc24-7e55-4069-a305-e2cded2db641 (opens source in a new tab)
Everolimus label
Version not recorded · Effective date not recorded
Plasma protein binding is approximately 74% both in healthy subjects and in patients with moderate hepatic impairment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e082a024-7850-400b-a5c2-2a140612562a (opens source in a new tab)
Everolimus label
Version not recorded · Effective date not recorded
Plasma protein binding is approximately 74% in healthy subjects and in patients with moderate hepatic impairment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:435da284-ef0e-ca90-e0db-bab9382922e0 (opens source in a new tab)
Everolimus label
Version not recorded · Effective date not recorded
Plasma protein binding is approximately 74% in healthy subjects and in patients with moderate hepatic impairment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01f7b5fb-be0d-4adf-acd2-6899018de966 (opens source in a new tab)
Everolimus label
Version not recorded · Effective date not recorded
Plasma protein binding is approximately 74% both in healthy subjects and in patients with moderate hepatic impairment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7bb6ba1-9a7f-43f5-b058-ef26d4b59221 (opens source in a new tab)
Everolimus label
Version not recorded · Effective date not recorded
Plasma protein binding is approximately 74% in healthy subjects and in patients with moderate hepatic impairment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c0075dd-a0a8-4dc4-be32-1be8383fbbdc (opens source in a new tab)
Everolimus label
Version not recorded · Effective date not recorded
Plasma protein binding is approximately 74% both in healthy subjects and in patients with moderate hepatic impairment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2150f73a-179b-4afc-b8ce-67c85cc72f04 (opens source in a new tab)
Everolimus label
Version not recorded · Effective date not recorded
Plasma protein binding is approximately 74% both in healthy subjects and in patients with moderate hepatic impairment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5cfca904-b75c-5a39-8cb9-b99bb421bceb (opens source in a new tab)
Everolimus label
Version not recorded · Effective date not recorded
Plasma protein binding is approximately 74% both in healthy subjects and in patients with moderate hepatic impairment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2693c497-a70b-4d00-b6db-602c872e5bed (opens source in a new tab)
Everolimus label
Version not recorded · Effective date not recorded
Plasma protein binding is approximately 74% in healthy subjects and in patients with moderate hepatic impairment.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5aaf2fb7-93f6-40d6-941a-9583a3794ce7 (opens source in a new tab)
Everolimus label
Version not recorded · Effective date not recorded
Plasma protein binding is approximately 74% both in healthy subjects and in patients with moderate hepatic impairment.
Projected row 573
- Medicine slug
- exemestane
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 10
- Source count
- 10
- Agreement rate
- 1
- Recorded readings
24 hours
- Numeric value
- 24
- Unit
- hours
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1841ec12-3f4f-4b87-b719-fd0b4d9eaffb (opens source in a new tab)
Exemestane label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following oral administration to healthy postmenopausal women, plasma concentrations of exemestane decline polyexponentially with a mean terminal half-life of about 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:69abd0ff-b200-4d1a-b14a-80e980a8e781 (opens source in a new tab)
Exemestane label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following oral administration to healthy postmenopausal women, plasma concentrations of exemestane decline polyexponentially with a mean terminal half-life of about 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1bbe1bd-fa92-4fdd-88df-31ebcb200d37 (opens source in a new tab)
Exemestane label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following oral administration to healthy postmenopausal women, plasma concentrations of exemestane decline polyexponentially with a mean terminal half-life of about 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e3fd382-19f5-4ded-ab22-39d5b1b2f366 (opens source in a new tab)
Exemestane label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following oral administration to healthy postmenopausal women, plasma concentrations of exemestane decline polyexponentially with a mean terminal half-life of about 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9354d1a1-8e8c-4c6a-b7ad-d4fe14b10a8b (opens source in a new tab)
Exemestane label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following oral administration to healthy postmenopausal women, plasma concentrations of exemestane decline polyexponentially with a mean terminal half-life of about 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e24b08eb-4693-41c7-81cb-b536947f7070 (opens source in a new tab)
Exemestane label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following oral administration to healthy postmenopausal women, plasma concentrations of exemestane decline polyexponentially with a mean terminal half-life of about 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:abde1ccd-0ec9-40d4-b205-fbc00f5878b9 (opens source in a new tab)
Exemestane label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following oral administration to healthy postmenopausal women, plasma concentrations of exemestane decline polyexponentially with a mean terminal half-life of about 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83db7b64-7e98-4bd5-83ce-37444e6dd971 (opens source in a new tab)
Exemestane label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following oral administration to healthy postmenopausal women, plasma concentrations of exemestane decline polyexponentially with a mean terminal half-life of about 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cf066b7a-032a-416c-8d40-15ba581423e3 (opens source in a new tab)
Exemestane label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following oral administration to healthy postmenopausal women, plasma concentrations of exemestane decline polyexponentially with a mean terminal half-life of about 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8bd17b4-5289-45bb-8095-de89dc8d39ed (opens source in a new tab)
Exemestane label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following oral administration to healthy postmenopausal women, plasma concentrations of exemestane decline polyexponentially with a mean terminal half-life of about 24 hours.
Projected row 574
- Medicine slug
- exemestane
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 10
- Source count
- 10
- Agreement rate
- 1
- Recorded readings
1.2 hours
- Numeric value
- 1.2
- Unit
- hours
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1841ec12-3f4f-4b87-b719-fd0b4d9eaffb (opens source in a new tab)
Exemestane label
Version not recorded · Effective date not recorded
Absorption Following oral administration, exemestane appeared to be absorbed more rapidly in women with breast cancer than in the healthy women, with a mean t max of 1.2 hours in the women with breast cancer and 2.9 hours in healthy women.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:69abd0ff-b200-4d1a-b14a-80e980a8e781 (opens source in a new tab)
Exemestane label
Version not recorded · Effective date not recorded
Absorption Following oral administration, exemestane appeared to be absorbed more rapidly in women with breast cancer than in the healthy women, with a mean t max of 1.2 hours in the women with breast cancer and 2.9 hours in healthy women.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1bbe1bd-fa92-4fdd-88df-31ebcb200d37 (opens source in a new tab)
Exemestane label
Version not recorded · Effective date not recorded
Absorption: Following oral administration, exemestane appeared to be absorbed more rapidly in women with breast cancer than in the healthy women, with a mean t max of 1.2 hours in the women with breast cancer and 2.9 hours in healthy women.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e3fd382-19f5-4ded-ab22-39d5b1b2f366 (opens source in a new tab)
Exemestane label
Version not recorded · Effective date not recorded
Absorption Following oral administration, exemestane appeared to be absorbed more rapidly in women with breast cancer than in the healthy women, with a mean t max of 1.2 hours in the women with breast cancer and 2.9 hours in healthy women.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9354d1a1-8e8c-4c6a-b7ad-d4fe14b10a8b (opens source in a new tab)
Exemestane label
Version not recorded · Effective date not recorded
Absorption Following oral administration, exemestane appeared to be absorbed more rapidly in women with breast cancer than in the healthy women, with a mean t max of 1.2 hours in the women with breast cancer and 2.9 hours in healthy women.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e24b08eb-4693-41c7-81cb-b536947f7070 (opens source in a new tab)
Exemestane label
Version not recorded · Effective date not recorded
Absorption Following oral administration, exemestane appeared to be absorbed more rapidly in women with breast cancer than in the healthy women, with a mean t max of 1.2 hours in the women with breast cancer and 2.9 hours in healthy women.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:abde1ccd-0ec9-40d4-b205-fbc00f5878b9 (opens source in a new tab)
Exemestane label
Version not recorded · Effective date not recorded
Absorption Following oral administration, exemestane appeared to be absorbed more rapidly in women with breast cancer than in the healthy women, with a mean t max of 1.2 hours in the women with breast cancer and 2.9 hours in healthy women.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83db7b64-7e98-4bd5-83ce-37444e6dd971 (opens source in a new tab)
Exemestane label
Version not recorded · Effective date not recorded
Absorption Following oral administration, exemestane appeared to be absorbed more rapidly in women with breast cancer than in the healthy women, with a mean t max of 1.2 hours in the women with breast cancer and 2.9 hours in healthy women.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cf066b7a-032a-416c-8d40-15ba581423e3 (opens source in a new tab)
Exemestane label
Version not recorded · Effective date not recorded
Absorption Following oral administration, exemestane appeared to be absorbed more rapidly in women with breast cancer than in the healthy women, with a mean t max of 1.2 hours in the women with breast cancer and 2.9 hours in healthy women.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8bd17b4-5289-45bb-8095-de89dc8d39ed (opens source in a new tab)
Exemestane label
Version not recorded · Effective date not recorded
Absorption Following oral administration, exemestane appeared to be absorbed more rapidly in women with breast cancer than in the healthy women, with a mean t max of 1.2 hours in the women with breast cancer and 2.9 hours in healthy women.
Projected row 575
- Medicine slug
- exenatide
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
2.4 hours
- Numeric value
- 2.4
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e6cb5c8f-e97f-4a6a-95a4-939fd2393949 (opens source in a new tab)
Exenatide label
Version not recorded · Effective date not recorded
The mean apparent clearance of exenatide in humans is 9.1 L/hour and the mean terminal half-life is 2.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53d03c03-ebf7-418d-88a8-533eabd2ee4f (opens source in a new tab)
Exenatide label
Version not recorded · Effective date not recorded
The mean apparent clearance of exenatide in humans is 9.1 L/hour and the mean terminal half-life is 2.4 hours.
Projected row 576
- Medicine slug
- exenatide
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
2.5 hours
- Numeric value
- 2.5
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e6cb5c8f-e97f-4a6a-95a4-939fd2393949 (opens source in a new tab)
Exenatide label
Version not recorded · Effective date not recorded
Digoxin Administration of repeated doses of exenatide (10 mcg BID) 30 minutes before oral digoxin (0.25 mg once daily) decreased the C max of digoxin by 17% and delayed the T max of digoxin by approximately 2.5 hours; however, the overall steady-state pharmacokinetic exposure (e.g., AUC) of digoxin was not changed.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53d03c03-ebf7-418d-88a8-533eabd2ee4f (opens source in a new tab)
Exenatide label
Version not recorded · Effective date not recorded
Digoxin Administration of repeated doses of BYETTA (10 mcg BID) 30 minutes before oral digoxin (0.25 mg once daily) decreased the C max of digoxin by 17% and delayed the T max of digoxin by approximately 2.5 hours; however, the overall steady-state pharmacokinetic exposure (e.g., AUC) of digoxin was not changed.
Projected row 577
- Medicine slug
- ezetimibe
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 40
- Source count
- 40
- Agreement rate
- 1
- Recorded readings
22 hours
- Numeric value
- 22
- Unit
- hours
- Source records
- 40
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 40 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57d19491-cba1-4720-b69d-481574459201 (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c92292f5-5444-4247-927e-db7bf6816109 (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:090776cf-f211-49a3-a993-ff5d707311f2 (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ebe3fa4e-82c4-4a9a-9aec-f64019391f4e (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a04678f-e961-45aa-b3bb-e38e66856edc (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6e77d9b-a553-63e0-e053-2a95a90a18fe (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6b4fd12-9954-42ba-b42a-56f3747c47ff (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1afdb764-c5da-4982-beae-9be61bdcbcdc (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f5644a9-e019-4e5d-ab6f-3d30b1024c5a (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6fcbfbd9-6e09-8224-e053-2a91aa0a8226 (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55b18d8f-40e0-48ba-baf1-79a0d1bb2ee2 (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5cbd9bce-e02d-440f-95d5-4eb958d2f4f3 (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11828685-dc27-42d8-a6ff-f110018207d1 (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11de499b-ad8a-46a6-9021-c8eba72ae414 (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd8a09cb-f014-4650-9da2-4ad1581c9741 (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4cfda5aa-e21a-47b2-b296-88d8336298ef (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:206d702c-b09a-4555-972b-6555d6d6d6e6 (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e257ed7f-5015-4f1d-93f4-5adf5797643d (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1cc2018-72a3-48bc-90de-c460f224cf5a (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3fadf4e9-017d-4ccd-91dc-a89b981eb138 (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a80b668-51cd-42be-8497-8712b0508422 (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e9a9eda-1b2a-4475-8483-0f410a17c524 (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02b00cb2-7253-4fb4-a216-53691a929a28 (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68247ce8-e812-42f2-a3ba-0f6e49acca63 (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03609879-bad2-4e75-83fe-1e1a2fd300c3 (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a78aa8d-1fe0-4df0-a15b-2350c15aead1 (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5877150f-2807-435e-8e5b-a07dc7dbfd27 (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ceecdbe9-5404-4a93-a488-9211cd103058 (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:174e45e0-45bb-48b7-9e60-8f6cfc1d22bb (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f852b12f-e25f-415b-b1e2-58955d609507 (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ebcb6655-fd60-4099-8099-be911c5b32ae (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:109a22f4-a7cb-96c6-e063-6394a90ad7f6 (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac539a72-77e4-419c-b1d9-42002e9cecf7 (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4158aa71-3540-4912-b909-7491e5a1429c (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbbe54c3-59a1-436c-aba8-188ba7ca70e0 (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b3842f6-c80a-47b8-8a82-b69e465b05f7 (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:726b1e63-437a-4b3b-b773-3ac47a5c0f38 (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:63ecbbf1-a6de-493f-9710-812ff45cb4d3 (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b128e52-5d0d-4536-aa1f-be192d0989ad (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c07fe2e0-dad4-48b5-8a07-7d57a4035ccd (opens source in a new tab)
Ezetimibe label
Version not recorded · Effective date not recorded
Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide.
Projected row 578
- Medicine slug
- famciclovir
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 12
- Source count
- 12
- Agreement rate
- 1
- Recorded readings
77 ± 8%
- Numeric value
- 77
- Unit
- %
- Source records
- 12
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 12 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c2b21ad5-fa83-1fb6-e053-2a95a90a3d0f (opens source in a new tab)
Famciclovir label
Version not recorded · Effective date not recorded
Pharmacokinetics in adults: Absorption and Bioavailability: The absolute bioavailability of penciclovir is 77 ± 8% as determined following the administration of a 500 mg famciclovir oral dose and a 400 mg penciclovir intravenous dose to 12 healthy male subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c44b8d2-3b70-4e8b-af03-2e917178f761 (opens source in a new tab)
Famciclovir label
Version not recorded · Effective date not recorded
Pharmacokinetics in adults: Absorption and Bioavailability: The absolute bioavailability of penciclovir is 77 ± 8% as determined following the administration of a 500 mg famciclovir oral dose and a 400 mg penciclovir intravenous dose to 12 healthy male subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5723f50e-b0fa-65f0-e063-6294a90a350f (opens source in a new tab)
Famciclovir label
Version not recorded · Effective date not recorded
Pharmacokinetics in adults: Absorption and Bioavailability: The absolute bioavailability of penciclovir is 77 ± 8% as determined following the administration of a 500 mg famciclovir oral dose and a 400 mg penciclovir intravenous dose to 12 healthy male subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:29b7ea8b-b976-45cb-9006-a27ba797b0fd (opens source in a new tab)
Famciclovir label
Version not recorded · Effective date not recorded
Pharmacokinetics in adults: Absorption and Bioavailability: The absolute bioavailability of penciclovir is 77 ± 8% as determined following the administration of a 500 mg famciclovir oral dose and a 400 mg penciclovir intravenous dose to 12 healthy male subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5c46506-a350-44a1-9440-d939da895f16 (opens source in a new tab)
Famciclovir label
Version not recorded · Effective date not recorded
Pharmacokinetics in adults: Absorption and Bioavailability: The absolute bioavailability of penciclovir is 77 ± 8% as determined following the administration of a 500 mg famciclovir oral dose and a 400 mg penciclovir intravenous dose to 12 healthy male subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c579bc7-8130-4935-a999-62b4b1c20706 (opens source in a new tab)
Famciclovir label
Version not recorded · Effective date not recorded
Pharmacokinetics in adults: Absorption and Bioavailability: The absolute bioavailability of penciclovir is 77 ± 8% as determined following the administration of a 500 mg famciclovir oral dose and a 400 mg penciclovir intravenous dose to 12 healthy male subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d3faac3a-5c8c-4987-9703-c161fb29ec56 (opens source in a new tab)
Famciclovir label
Version not recorded · Effective date not recorded
Pharmacokinetics in adults: Absorption and Bioavailability: The absolute bioavailability of penciclovir is 77 ± 8% as determined following the administration of a 500 mg famciclovir oral dose and a 400 mg penciclovir intravenous dose to 12 healthy male subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eeeee9c4-8566-4100-8ca4-3df936a3365d (opens source in a new tab)
Famciclovir label
Version not recorded · Effective date not recorded
Pharmacokinetics in adults: Absorption and Bioavailability: The absolute bioavailability of penciclovir is 77 ± 8% as determined following the administration of a 500 mg famciclovir oral dose and a 400 mg penciclovir intravenous dose to 12 healthy male subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b75abffb-0a90-4abd-8ed8-81be1d8fe364 (opens source in a new tab)
Famciclovir label
Version not recorded · Effective date not recorded
Pharmacokinetics in adults: Absorption and Bioavailability: The absolute bioavailability of penciclovir is 77 ± 8% as determined following the administration of a 500 mg famciclovir oral dose and a 400 mg penciclovir intravenous dose to 12 healthy male subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f02042f-8f51-4ccf-b608-5dcd75d100fb (opens source in a new tab)
Famciclovir label
Version not recorded · Effective date not recorded
Pharmacokinetics in adults: Absorption and Bioavailability: The absolute bioavailability of penciclovir is 77 ± 8% as determined following the administration of a 500 mg famciclovir oral dose and a 400 mg penciclovir intravenous dose to 12 healthy male subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08c58224-5920-4853-8c59-ec5fbb66c2f6 (opens source in a new tab)
Famciclovir label
Version not recorded · Effective date not recorded
Pharmacokinetics in adults: Absorption and Bioavailability: The absolute bioavailability of penciclovir is 77 ± 8% as determined following the administration of a 500 mg famciclovir oral dose and a 400 mg penciclovir intravenous dose to 12 healthy male subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fcf0b0fa-bb2c-4f2c-aa9f-1f2da65d8343 (opens source in a new tab)
Famciclovir label
Version not recorded · Effective date not recorded
Pharmacokinetics in adults: Absorption and Bioavailability: The absolute bioavailability of penciclovir is 77 ± 8% as determined following the administration of a 500 mg famciclovir oral dose and a 400 mg penciclovir intravenous dose to 12 healthy male subjects.
Projected row 579
- Medicine slug
- famciclovir
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 12
- Source count
- 12
- Agreement rate
- 0.833333
- Recorded readings
2.0±0.3 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c2b21ad5-fa83-1fb6-e053-2a95a90a3d0f (opens source in a new tab)
Famciclovir label
Version not recorded · Effective date not recorded
The plasma elimination half-life of penciclovir was 2.0±0.3 hours after intravenous administration of penciclovir to 48 healthy male volunteers and 2.3±0.4 hours after oral administration of 500 mg famciclovir to 124 healthy male volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c44b8d2-3b70-4e8b-af03-2e917178f761 (opens source in a new tab)
Famciclovir label
Version not recorded · Effective date not recorded
The plasma elimination half-life of penciclovir was 2.0±0.3 hours after intravenous administration of penciclovir to 48 healthy male volunteers and 2.3±0.4 hours after oral administration of 500 mg famciclovir to 124 healthy male volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5723f50e-b0fa-65f0-e063-6294a90a350f (opens source in a new tab)
Famciclovir label
Version not recorded · Effective date not recorded
The plasma elimination half-life of penciclovir was 2.0 ± 0.3 hours after intravenous administration of penciclovir to 48 healthy male volunteers and 2.3 ± 0.4 hours after oral administration of 500 mg famciclovir to 124 healthy male volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:29b7ea8b-b976-45cb-9006-a27ba797b0fd (opens source in a new tab)
Famciclovir label
Version not recorded · Effective date not recorded
The plasma elimination half-life of penciclovir was 2.0 ± 0.3 hours after intravenous administration of penciclovir to 48 healthy male volunteers and 2.3 ± 0.4 hours after oral administration of 500 mg famciclovir to 124 healthy male volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c579bc7-8130-4935-a999-62b4b1c20706 (opens source in a new tab)
Famciclovir label
Version not recorded · Effective date not recorded
The plasma elimination half-life of penciclovir was 2.0 ± 0.3 hours after intravenous administration of penciclovir to 48 healthy male volunteers and 2.3 ± 0.4 hours after oral administration of 500 mg famciclovir to 124 healthy male volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d3faac3a-5c8c-4987-9703-c161fb29ec56 (opens source in a new tab)
Famciclovir label
Version not recorded · Effective date not recorded
The plasma elimination half-life of penciclovir was 2.0±0.3 hours after intravenous administration of penciclovir to 48 healthy male volunteers and 2.3±0.4 hours after oral administration of 500 mg famciclovir to 124 healthy male volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eeeee9c4-8566-4100-8ca4-3df936a3365d (opens source in a new tab)
Famciclovir label
Version not recorded · Effective date not recorded
The plasma elimination half-life of penciclovir was 2.0±0.3 hours after intravenous administration of penciclovir to 48 healthy male volunteers and 2.3±0.4 hours after oral administration of 500 mg famciclovir to 124 healthy male volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b75abffb-0a90-4abd-8ed8-81be1d8fe364 (opens source in a new tab)
Famciclovir label
Version not recorded · Effective date not recorded
The plasma elimination half-life of penciclovir was 2.0±0.3 hours after intravenous administration of penciclovir to 48 healthy male volunteers and 2.3±0.4 hours after oral administration of 500 mg famciclovir to 124 healthy male volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f02042f-8f51-4ccf-b608-5dcd75d100fb (opens source in a new tab)
Famciclovir label
Version not recorded · Effective date not recorded
The plasma elimination half-life of penciclovir was 2.0±0.3 hours after intravenous administration of penciclovir to 48 healthy male volunteers and 2.3±0.4 hours after oral administration of 500 mg famciclovir to 124 healthy male volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08c58224-5920-4853-8c59-ec5fbb66c2f6 (opens source in a new tab)
Famciclovir label
Version not recorded · Effective date not recorded
The plasma elimination half-life of penciclovir was 2.0 ± 0.3 hours after intravenous administration of penciclovir to 48 healthy male volunteers and 2.3 ± 0.4 hours after oral administration of 500 mg famciclovir to 124 healthy male volunteers.
2±0.3 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5c46506-a350-44a1-9440-d939da895f16 (opens source in a new tab)
Famciclovir label
Version not recorded · Effective date not recorded
The plasma elimination half-life of penciclovir was 2±0.3 hours after intravenous administration of penciclovir to 48 healthy male volunteers and 2.3±0.4 hours after oral administration of 500 mg famciclovir to 124 healthy male volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fcf0b0fa-bb2c-4f2c-aa9f-1f2da65d8343 (opens source in a new tab)
Famciclovir label
Version not recorded · Effective date not recorded
The plasma elimination half-life of penciclovir was 2±0.3 hours after intravenous administration of penciclovir to 48 healthy male volunteers and 2.3±0.4 hours after oral administration of 500 mg famciclovir to 124 healthy male volunteers.
Projected row 580
- Medicine slug
- famciclovir
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 12
- Source count
- 10
- Agreement rate
- 1
- Recorded readings
1 hour
- Numeric value
- 1
- Unit
- hours
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c2b21ad5-fa83-1fb6-e053-2a95a90a3d0f (opens source in a new tab)
Famciclovir label
Version not recorded · Effective date not recorded
There was an 18% decrease in C max and a delay in t max of about 1 hour when famciclovir was given 2 hours after a meal as compared to its administration 2 hours before a meal.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c44b8d2-3b70-4e8b-af03-2e917178f761 (opens source in a new tab)
Famciclovir label
Version not recorded · Effective date not recorded
There was an 18% decrease in C max and a delay in t max of about 1 hour when famciclovir was given 2 hours after a meal as compared to its administration 2 hours before a meal.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5723f50e-b0fa-65f0-e063-6294a90a350f (opens source in a new tab)
Famciclovir label
Version not recorded · Effective date not recorded
There was an 18% decrease in C max and a delay in t max of about 1 hour when famciclovir was given 2 hours after a meal as compared to its administration 2 hours before a meal.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:29b7ea8b-b976-45cb-9006-a27ba797b0fd (opens source in a new tab)
Famciclovir label
Version not recorded · Effective date not recorded
There was an 18% decrease in C max and a delay in t max of about 1 hour when famciclovir was given 2 hours after a meal as compared to its administration 2 hours before a meal.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c579bc7-8130-4935-a999-62b4b1c20706 (opens source in a new tab)
Famciclovir label
Version not recorded · Effective date not recorded
There was an 18% decrease in C max and a delay in t max of about 1 hour when famciclovir was given 2 hours after a meal as compared to its administration 2 hours before a meal.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d3faac3a-5c8c-4987-9703-c161fb29ec56 (opens source in a new tab)
Famciclovir label
Version not recorded · Effective date not recorded
There was an 18% decrease in C max and a delay in t max of about 1 hour when famciclovir was given 2 hours after a meal as compared to its administration 2 hours before a meal.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eeeee9c4-8566-4100-8ca4-3df936a3365d (opens source in a new tab)
Famciclovir label
Version not recorded · Effective date not recorded
There was an 18% decrease in C max and a delay in t max of about 1 hour when famciclovir was given 2 hours after a meal as compared to its administration 2 hours before a meal.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b75abffb-0a90-4abd-8ed8-81be1d8fe364 (opens source in a new tab)
Famciclovir label
Version not recorded · Effective date not recorded
There was an 18% decrease in C max and a delay in t max of about 1 hour when famciclovir was given 2 hours after a meal as compared to its administration 2 hours before a meal.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f02042f-8f51-4ccf-b608-5dcd75d100fb (opens source in a new tab)
Famciclovir label
Version not recorded · Effective date not recorded
There was an 18% decrease in C max and a delay in t max of about 1 hour when famciclovir was given 2 hours after a meal as compared to its administration 2 hours before a meal.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08c58224-5920-4853-8c59-ec5fbb66c2f6 (opens source in a new tab)
Famciclovir label
Version not recorded · Effective date not recorded
There was an 18% decrease in C max and a delay in t max of about 1 hour when famciclovir was given 2 hours after a meal as compared to its administration 2 hours before a meal.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=570Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.